Skip to content

Study · Case report or series · n = 1 · 2016

3 results

Congenital Methemoglobinemia Type II-Clinical Improvement with Short-Term Methylene Blue Treatment.

Cooper MS, Randall M, Rowell M, Charlton M, Greenway A, Barnes C

Pediatric blood & cancer17 Nov 2015Cited by 17 (Europe PMC)

PMID26574897 (opens in a new tab)DOI10.1002/pbc.25791 (opens in a new tab)PepBankPUB-26574897
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a boy with congenital methemoglobinemia type II, methemoglobin levels were significantly lower after prophylactic methylene blue began.

    In plain wordsIn a boy with congenital methemoglobinemia, methemoglobin levels decreased significantly after prophylactic methylene blue began.

    Peptide
    Methylene blue
    Outcome
    DecreaseMethemoglobin level
    Study

    n = 1

    Outcome group
    Blood oxygenation and oxygen transport · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Since the MB treatment regimen has commenced, his methemoglobin level has been significantly lower.
    2 context sentences
    Summary · context
    We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia type II.
    Summary · context
    He has a CYB5R3 compound heterozygote mutation, causing a cytochrome-b(5) reductase deficiency.
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with congenital methemoglobinemia type II, behavior showed modest improvement after prophylactic methylene blue began.

    In plain wordsIn a boy with congenital methemoglobinemia, behavior improved modestly after prophylactic methylene blue began.

    Peptide
    Methylene blue
    Outcome
    IncreaseBehavioral improvement
    Study

    n = 1

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    He has shown modest behavioral improvements (as assessed on the Achenbach behavior report scales).
    2 context sentences
    Summary · context
    We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia type II.
    Summary · context
    He has a CYB5R3 compound heterozygote mutation, causing a cytochrome-b(5) reductase deficiency.
  3. 03HumanCase report or seriesSafety outcome

    In a boy with congenital methemoglobinemia type II, prophylactic methylene blue produced no reported iatrogenic side effects.

    In plain wordsIn a boy with congenital methemoglobinemia, no treatment-related side effects were reported with prophylactic methylene blue.

    Peptide
    Methylene blue
    Outcome
    Not applicableIatrogenic side effects
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There have been no iatrogenic side effects.
    2 context sentences
    Summary · context
    We report a case of prophylactic management with methylene blue (MB) in an almost 4-year-old male with congenital methemoglobinemia type II.
    Summary · context
    He has a CYB5R3 compound heterozygote mutation, causing a cytochrome-b(5) reductase deficiency.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.